olopatadine-hydrochloride and Nasal-Obstruction

Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

Topics: Activities of Daily Living; Administration, Intranasal; Clinical Trials as Topic; Dibenzoxepins; Drug Approval; Epistaxis; Histamine H1 Antagonists, Non-Sedating; Nasal Obstruction; Olopatadine Hydrochloride; Quality of Life; Rhinitis, Allergic, Seasonal

We investigated the effect of KW-4679 (Z-11-(dimethylaminopropyliden)-6,11-dihydrodibenzoxepin-2-a cetic acid hydrochloride), an antiallergic agent, on the nasal blockage induced by antigen challenge into the nostrils of actively sensitized guinea pigs. The change of the nasal cavity volume caused by nasal mucosal swelling after antigen challenge was measured by acoustic rhinometry. Oral administration of KW-4679 (0.01-10 mg/kg) significantly inhibited the decrease in the nasal cavity volume at 10 min, 30 min and 6 hr after antigen challenge. Ketotifen (1-10 mg/kg, p.o.) also inhibited the decrease in the nasal cavity volume after antigen challenge. These results indicate that KW-4679 may be useful for the treatment of allergic rhinitis.

Topics: Animals; Dibenzoxepins; Disease Models, Animal; Guinea Pigs; Male; Nasal Cavity; Nasal Obstruction; Olopatadine Hydrochloride; Rhinitis; Time Factors